- CISMeF

CISMeF

chu

Strategia di Ricerca CISMeF

richiesta (CISMeF) : effets indésirables des médicaments.ti ou (toxicité des médicaments.mc ou hypersensibilité médicamenteuse.mc ou ergotisme.mc ou syndrome malin des neuroleptiques.mc ou lésions hépatiques dues aux substances.mc ou actions pharmacologiques/effets indésirables.mc ou (médicaments.mt et effets indésirables.qu) ou malformations dues aux médicaments et aux drogues.mc ou psychoses toxiques.mc);

Richiesta PubMed (proposta da CISMeF) : %22drug adverse effects%22[TIAB] OR (%22Drug-Related side effects and adverse reactions%22[MH] OR %22drug hypersensitivity%22[MH] OR %22ergotism%22[MH] OR %22neuroleptic malignant syndrome%22[MH] OR %22Drug-Induced liver injury%22[MH] OR %22pharmacologic actions/adverse effects%22[MH] OR (%22abnormalities, drug-induced%22[MH] OR %22administration and dosage%22[SH] OR %22biological products%22[MH] OR %22biomarkers, pharmacological%22[MH] OR %22Bisphosphonate-Associated osteonecrosis of the jaw%22[MH] OR %22databases, pharmaceutical%22[MH] OR %22drug administration routes%22[MH] OR %22drug administration schedule%22[MH] OR %22drug adverse effects%22[TIAB] OR (%22Drug-Related side effects and adverse reactions%22[MH] OR %22drug hypersensitivity%22[MH] OR %22ergotism%22[MH] OR %22neuroleptic malignant syndrome%22[MH] OR %22Drug-Induced liver injury%22[MH] OR %22pharmacologic actions/adverse effects%22[MH] OR (%22adverse effects%22[SH]) OR %22abnormalities, drug-induced%22[MH] OR %22psychoses, substance-induced%22[MH]) OR %22drug approval%22[MH] OR %22drug contamination%22[MH] OR %22drug costs%22[MH] OR %22drug effects%22[SH] OR %22drug evaluation, preclinical%22[MH] OR %22drug evaluation%22[MH] OR %22drug hypersensitivity%22[MH] OR %22drug induced neuropathies%22[TIAB] OR () OR %22drug monitoring%22[MH] OR %22drug recalls%22[MH] OR %22drug residues%22[MH] OR %22drug therapy%22[MH] OR %22drug therapy%22[SH] OR %22drug utilization%22[MH] OR %22Drug-Eluting stents%22[MH] OR %22drug-induced hypokalemia%22[TIAB] OR () OR %22Drug-Induced liver injury%22[MH] OR %22Drug-Related side effects and adverse reactions%22[MH] OR %22formularies as topic%22[MH] OR %22formularies%22 OR %22medication adherence%22[MH] OR %22medication systems%22[MH] OR %22orphan drug production%22[MH] OR %22pharmaceutical preparations%22[MH] OR %22pharmacokinetics%22[SH] OR %22pharmacologic actions%22[MH] OR %22pharmacological phenomena%22[MH] OR %22pharmacology%22[MH] OR %22prescription drug diversion%22[MH] OR %22refractory depression%22[TIAB] OR (() AND ()) OR %22Safety-Based drug withdrawals%22[MH] OR %22technology, pharmaceutical%22[MH] AND %22adverse effects%22[SH]) OR %22abnormalities, drug-induced%22[MH] OR %22psychoses, substance-induced%22[MH])

Dettagli

Identificatore unico

SR99999026;

Allineamento/i automatico/i CISMeF controllato/i
- Reazione avversa da farmaci [Termine Preferito MedDRA]
- Reazione avversa da farmaci NAS [Termine di basso livello MedDRA]
- Reazioni avv da medic dose appr [Descrittore CISP-2]
- Reazioni farmacologiche avverse [Composto LOINC]
- effetti collaterali dei farmaci e reazioni avverse [Descrittore MeSH]
- effetto indesiderato del farmaco [Termine di basso livello MedDRA]

Posizione della parola chiave nella/e arborescenza/e :

Consultare qui sotto una selezione delle risorse principali:

You can consult :

recommendations
documents concerning education
documents for patients

Nous contacter.
25/10/2025

[Homepage] [Inizio pagina]

© CHU di Rouen. Qualsiasi utilizzo parziale o totale di questo documento deve menzionare la fonte.